FDA Scrutiny of Novo Nordisk's Reporting Practices for Ozempic

Novo Nordisk, the manufacturer of the popular weight-loss and diabetes medications Ozempic and Wegovy, is under scrutiny from the U.S. Food and Drug Administration (FDA) following a warning letter that accuses the company of failing to adequately report serious side effects associated with its drugs. The FDA's concerns stem from an inspection that revealed systemic failures in Novo Nordisk's monitoring and reporting systems for adverse reactions, including deaths and severe health complications.

Ozempic side effects: Did Ozempic manufacturer Novo Nordisk hide drug death reports? Here’s what FDA said about side-effect reporting

The FDA's warning letter highlighted five specific cases where Novo Nordisk allegedly did not report serious adverse events involving patients taking semaglutide medications. These incidents included strokes, suicidal thoughts, and fatalities. Under U.S. law, pharmaceutical companies are required to report serious adverse events to the FDA within 15 days, regardless of whether a direct link to the medication is established. The FDA's findings suggest that Novo Nordisk did not consistently adhere to this requirement.

Ozempic side effects: Did Ozempic manufacturer Novo Nordisk hide drug death reports? Here’s what FDA said about side-effect reporting

Following the inspection in early 2025, there was a notable increase in adverse event reports submitted by Novo Nordisk, with nearly 11,000 reports filed in one week of July 2025. Among these, over 1,800 were categorized as serious, involving life-threatening reactions or death. Since 2020, the company has submitted more than 50,000 reports related to semaglutide, including at least 600 deaths. However, it is important to note that these reports do not confirm causation between the drug and the reported events.

Ozempic side effects: Did Ozempic manufacturer Novo Nordisk hide drug death reports? Here’s what FDA said about side-effect reporting

In response to the FDA's warning, Novo Nordisk expressed confidence in the safety profile of its GLP-1 medications, asserting that adverse event reports do not establish a direct cause-and-effect relationship. The company stated, “Novo Nordisk takes reporting requirements seriously and is committed to resolving the issues raised by the FDA.” Additionally, the company has begun updating its internal policies to address the concerns outlined in the warning letter.

Ozempic side effects: Did Ozempic manufacturer Novo Nordisk hide drug death reports? Here’s what FDA said about side-effect reporting

The FDA's warning letter comes amid growing legal challenges against manufacturers of GLP-1 medications, with thousands of patients filing lawsuits alleging that companies like Novo Nordisk failed to adequately inform users about potential risks. These lawsuits cite severe health complications, including intestinal blockages and neurological disorders. Legal experts suggest that the FDA's findings could significantly impact ongoing litigation against Novo Nordisk.

Ozempic side effects: Did Ozempic manufacturer Novo Nordisk hide drug death reports? Here’s what FDA said about side-effect reporting

Despite the controversies surrounding Ozempic and Wegovy, these medications remain widely used in the United States, with estimates indicating that over 31 million American adults are currently using GLP-1 medications. While many patients report successful weight loss with manageable side effects, the FDA continues to monitor the long-term safety of these drugs. As of now, no penalties have been imposed on Novo Nordisk, but the FDA's warning serves as a critical step in ensuring compliance with reporting regulations.

Ozempic side effects: Did Ozempic manufacturer Novo Nordisk hide drug death reports? Here’s what FDA said about side-effect reporting